Skip to content

comparison of intravenous sodium valproate versus subcutaneous sumatriptan and intramuscular metoclopramide for treatment of acute migraine attacks

clinical trial of comparison between intravenous sodium valproate and subcutaneous sumatriptan with intramuscular metoclopramide for treatment of acute attacks in patients with migraine headaches

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201104096154N1
Enrollment
60
Registered
2011-06-07
Start date
2011-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine without aura. Migraine without aura [common migraine]

Interventions

Sodium Valproate 400 mg single dose diluted in 100 cc Normal Saline infusion over 10 minutes
Intervention 1: Single dose 10 mg intramuscular Metoclopramide injection followed 10 minutes later by single dose 6 mg subcutaneous Sumatriptan injection. Intervention 2: Sodium Valproate 400 mg s
Treatment - Drugs
Single dose 10 mg intramuscular Metoclopramide injection followed 10 minutes later by single dose 6 mg subcutaneous Sumatriptan injection

Sponsors

Guilan University of Medical Science, Vice chancellor for research
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 70 Years

Inclusion criteria

Inclusion criteria: inclusion criteria include :fulfilling international headache society criteria for migraine without aura; absence of cardiovascular disease; absence of cerebrovascular disease; absence of drug allergy; absence of pregnancy; age between 16 to70 year-old. Exclusion criteria include :occurrence of serious adverse drug effects at any time during drug administration.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Headache severity. Timepoint: before treatment,after 2, 4 , and 24 hours. Method of measurement: visual analog scale.

Secondary

MeasureTime frame
Side effects profile. Timepoint: before treatment ,after 2 , 4, and 24 hours. Method of measurement: history taking and physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hamidreza Hatamian

Poorsina hospital of Rasht, Guilan University of Medical Sciences

babak.bakh@gmail.com+98 13 1322 2444

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026